AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Intrasense Board/Management Information 2014

Dec 23, 2014

1447_iss_2014-12-23_512bf293-93a2-4a84-93e0-0c9a7331d032.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

PRESS RELEASE

Stéphane Chemouny appointed Chairman and CEO of Intrasense

Montpellier, December 23, 2014: Intrasense (FR0011179886 - ALINS), global leader in multimodal medical imaging software solutions for oncology and chronic diseases, today announces that the Board of Directors has appointed Stéphane Chemouny as Chairman and CEO of Intrasense.

Stéphane Chemouny, specialist in scanners image processing, founded the Company in 2004 as a result of his research work. Intrasense has gradually established itself as a key player on its sector thanks to its intensive Research & Development work, a rigorous industrial approach and the appeal of its offer. The appointment of Stéphane Chemouny as Chairman and CEO is a major milestone for Intrasense, which – in a difficult geopolitical environment – is continuing to implement its strategy of refocusing its activity on the oncologic imaging sector and on the strategic markets with the highest potential (Asia, Europe, United States).

About Intrasense:

Created in 2004 with an innovative technology for detecting tissues in scanners, Intrasense designs, develops and markets Myrian®, a unique, vendor-neutral software suite for the visualization and advanced processing of multimodal medical images such as MRI, scanners, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian® combines and uses all of the various medical images to extract information vital to the patient's care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 - ALINS). The company employs 70 people, including 25 devoted to R&D. Labeled an "innovative company" by Oseo, Intrasense has invested over €10m in R&D since its creation.

For more about Intrasense, please visit www.intrasense.fr.

CONTACTS

Intrasense Christophe Lamboeuf, CFO Tel.: +33 (0)1 48 04 32 83 [email protected]

NewCap Financial communication & Investor relations Valentine Brouchot / Pierre Laurent Tel.: +33 (0)1 44 71 94 96 [email protected]